Reduction of HbA1c with dulaglutide in type 2 diabetes (T2D) patients negative, low positive or high positive for GAD antibodies (GADA): a post hoc analysis of AWARD-2,-4 and-5

被引：0
|
作者：
Pozzilli, P. [1 ]
Leslie, R. D. [2 ]
Peters, A. [3 ]
Buzzetti, R. [4 ]
Shankar, S. S. [5 ]
Milicevic, Z. [6 ]
Pavo, I. [6 ]
Lebrec, J. [7 ]
Martin, S. [5 ]
Schloot, N. [7 ]
机构：
[1] Univ Campus Biomed, Dept Endocrinol & Diabet, Rome, Italy
[2] Blizard Inst, London, England
[3] USC, Keck Sch Med, Dept Endocrinol & Diabet, Los Angeles, CA USA
[4] Sapienza Univ Rome, Dept Expt Med, Rome, Italy
[5] Eli Lilly & Co, Indianapolis, IN 46285 USA
[6] Eli Lilly & Co, Vienna, Austria
[7] Lilly Deutschland GmbH, Bad Homburg, Germany
来源：
DIABETOLOGIA | 2017年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
145
引用
收藏
页码：S68 / S68
页数：1
相关论文
共 50 条
  • [1] Reduction of A1c with Dulaglutide in Type 2 Diabetes (T2D) Patients Positive or Negative for GAD Antibodies (GADA): A Post-hoc Analysis of AWARD-2,-4, and-5
    Pozzilli, Paolo
    Leslie, Richard D.
    Peters, Anne
    Buzzetti, Raffaella
    Milicevic, Zvonko
    Pavo, Imre
    Lebrec, Jeremie
    Martin, Sherry
    Schloot, Nanette
    DIABETES, 2017, 66 : A287 - A287
  • [2] Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis
    Miao Yu
    Guo Yue Yuan
    Bin Zhang
    Hai Ya Wu
    Xiao Feng Lv
    Diabetes Therapy, 2020, 11 : 1147 - 1159
  • [3] Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis
    Yu, Miao
    Yuan, Guo Yue
    Zhang, Bin
    Wu, Hai Ya
    Lv, Xiao Feng
    DIABETES THERAPY, 2020, 11 (05) : 1147 - 1159
  • [4] Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2,-4 and-5 Trials
    Pozzilli, Paolo
    Leslie, Richard D.
    Peters, Anne L.
    Buzzetti, Raffaella
    Shankar, Sudha S.
    Milicevic, Zvonko
    Pavo, Imre
    Lebrec, Jeremie
    Martin, Sherry
    Schloot, Nanette C.
    DIABETES OBESITY & METABOLISM, 2018, 20 (06): : 1490 - 1498
  • [5] Efficacy of Dulaglutide (DU) as First Injectable Option for Patients with Type 2 Diabetes (T2D): A Post Hoc Pooled Analysis
    Patel, Hiren
    Munir, Kashif M.
    Sutherland, Sindee S.
    Konig, Manige
    DIABETES, 2019, 68
  • [6] Comment on: "Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2,-4 and-5 trials"
    Jones, Angus G.
    McDonald, Timothy J.
    DIABETES OBESITY & METABOLISM, 2018, 20 (06): : 1549 - 1550
  • [7] Response to the comment on: "Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2,-4 and-5 trials"
    Leslie, Richard D.
    Pozzilli, Paolo
    Peters, Anne L.
    Buzzetti, Raffaella
    Shankar, Sudha S.
    Milicevic, Zvonko
    Pavo, Imre
    Lebrec, Jeremie
    Martin, Sherry
    Schloot, Nanette C.
    DIABETES OBESITY & METABOLISM, 2018, 20 (09): : 2319 - 2320
  • [8] Impact of BMI on HbA1c Reduction, Hypoglycemia Rates, and Insulin Requirements in Response to IDegLira in Patients with Type 2 Diabetes (T2D)
    Buse, John B.
    Rodbard, Helena W.
    Woo, Vincent C.
    Vilsboll, Tina
    La Bandier, Micha
    Korsholm, Lars
    Gough, Stephen
    DIABETES, 2014, 63 : A18 - A18
  • [9] Higher Doses of Dulaglutide Induce Weight Loss in Patients with Type 2 Diabetes (T2D) Regardless of Baseline BMI: Post-hoc Analysis of AWARD-11
    Bonora, Enzo
    Frias, Juan P.
    Malik, Raleigh
    Kwan, Anita
    Raha, Sohini
    Bethel, Angelyn
    Cox, David
    DIABETES, 2021, 70
  • [10] Effect of tirzepatide in GADA-positive individuals with type 2 diabetes: a post hoc analysis of the SURPASS 2-5 trials
    Buzzetti, R.
    Peters, A. L.
    Lee, C. J.
    Pavo, I.
    Liu, M.
    Paik, J. S.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S312 - S312
12345